Shih Lee-Yung, Huang Chein-Fuang, Wu Jin-Hou, Wang Po-Nan, Lin Tung-Liang, Dunn Po, Chou Meng-Chu, Kuo Ming-Chung, Tang Chung-Chih
Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, and Chang Gung University, Taoyuan, Taiwan.
Clin Cancer Res. 2004 Feb 15;10(4):1326-32. doi: 10.1158/1078-0432.ccr-0835-03.
We analyzed Asp(835) mutations of FLT3 on paired marrow samples at diagnosis and relapse from 120 adult patients with de novo acute myeloid leukemia (AML) to determine the role of FLT3 Asp(835) mutation in the relapse of AML.
Asp(835) mutation was analyzed by DNA PCR amplification of exon 20 of FLT3 gene followed by EcoRV digestion. All of the mutations were confirmed by sequence analysis. Mutant to wild-type allelic ratio was determined by Genescan analysis. The Expand Long Template PCR System was used to determine the allelic location of internal tandem duplication of FLT3 (FLT3/ITD) and Asp(835) mutations.
Thirteen patients had Asp(835) mutations at diagnosis, of them 8 lost the mutations at relapse, and the remaining 5 patients carrying Asp(835) mutations at diagnosis relapsed with the identical mutation types. Another 6 patients acquired Asp(835) mutations at relapse. Five samples harbored both FLT3/ITD and Asp(835) mutations that were found on different alleles by cloning analysis in the 3 patients studied. There were no differences in WBC count, French-American-British subtype, percentage of marrow blasts, or circulating blasts between patients with and without Asp(835) mutations, whereas the difference in the prevalence of Asp(835) mutations among cytogenetic/molecular subgroups was statistically significant (P = 0.025).
The present study showed that patients with AML had heterogeneous patterns of FLT3 Asp(835) mutations, either acquisition or loss of the mutations at relapse. Asp(835) mutant clone may develop as a secondary event in a subset of patients with AML.
我们分析了120例初发成人急性髓系白血病(AML)患者诊断时和复发时配对骨髓样本中FLT3的天冬氨酸(Asp)(835)突变,以确定FLT3 Asp(835)突变在AML复发中的作用。
通过FLT3基因第20外显子的DNA PCR扩增,随后进行EcoRV酶切分析Asp(835)突变。所有突变均经序列分析证实。通过基因扫描分析确定突变型与野生型等位基因比例。使用扩展长模板PCR系统确定FLT3内部串联重复(FLT3/ITD)和Asp(835)突变的等位基因位置。
13例患者在诊断时有Asp(835)突变,其中8例在复发时突变消失,其余5例诊断时携带Asp(835)突变的患者复发时突变类型相同。另外6例患者在复发时获得了Asp(835)突变。在研究的3例患者中,通过克隆分析发现5个样本同时存在FLT3/ITD和Asp(835)突变,且位于不同等位基因上。有或无Asp(835)突变的患者在白细胞计数、法美英亚型、骨髓原始细胞百分比或循环原始细胞方面无差异,而细胞遗传学/分子亚组中Asp(835)突变的发生率差异具有统计学意义(P = 0.025)。
本研究表明,AML患者的FLT3 Asp(835)突变模式具有异质性,复发时可能出现突变的获得或丢失。Asp(835)突变克隆可能在一部分AML患者中作为继发事件出现。